The research team, led by Professors Kimberly Kline and Mary Chan, developed the peptide knowns as CSM5-K5 with chitosan, a sugar found in crustacean shells that is structurally similar to bacterial cell walls. They believe that this resemblance allows the peptide to embed itself on the cell wall and membrane, causing defects and re-establishing the bacteria’s sensitivity to known antibiotics. CSM5-K5 even killed 99% of common biofilm bacteria in the lab and over 90% of biofilm on mice wounds without toxicity to healthy cells.

Further studies must be done on the efficacy and economics of combination therapies for treating MDR infections. While many research efforts are currently focused on dealing with the COVID-19 pandemic, Professor Chan reiterates that “we should also remember that antibiotic resistance continues to be a growing problem, where secondary bacterial infections that develop in patients could complicate matters, posing a threat in the healthcare settings.”

Medicare fines half of hospitals for readmitting too many patients

Kaiser Health News recently reported that...

Don’t let the term ‘elective’ fool you, physicians urge the public

According to Becker’s Hospital Review, the...

CDC to spend $2.1B to bolster US infection control and prevention efforts

Becker’s Hospital Review recently reported on...

Hospital floors a greater source of infection than previously thought

The floors of patient rooms in hospitals are...

To fight surgical superbugs, WHO recommends new guidelines

The World Health Organization (WHO) stated that...

Super bacterias mortales destruidas por ejercicios moleculares

Investigadores de la Universidad de Rice, la...

Tasmanian devil milk fights superbugs

According to Australian researchers, milk from...

WHO launches first ever global report on infection prevention and control

WHO launches first ever global report on...

Current Use of Bone Substitutes in Maxillofacial Surgery

sulfato-de-calcio-en-cirugia-p...

Distribuidor exclusivo.

0